Avotermin

Avotermin is a protein that is used in the field of medicine and biotechnology. It is a recombinant human transforming growth factor beta 3 (rhTGFβ3) and is used for the improvement of wound healing and the reduction of scar formation.

History

Avotermin was developed by Renovo, a biopharmaceutical company based in Manchester, United Kingdom. The company was founded in 1998 by Mark Ferguson and Sharon O'Kane with the aim of developing drugs to improve wound healing and reduce scarring.

Mechanism of Action

Avotermin works by promoting the production of extracellular matrix proteins and reducing inflammation. It does this by binding to the TGFβ receptor on the surface of cells, which triggers a cascade of events leading to the production of extracellular matrix proteins and the reduction of inflammation.

Clinical Trials

Avotermin has undergone several clinical trials to test its efficacy and safety. In a Phase II clinical trial, it was found to significantly improve the appearance of scars compared to a placebo. However, in a Phase III clinical trial, it failed to meet its primary endpoint of improving the appearance of scars.

Future Development

Despite the setback in the Phase III clinical trial, Renovo continues to develop avotermin and other drugs for the improvement of wound healing and the reduction of scarring. The company believes that avotermin has the potential to be a breakthrough treatment for patients with severe scarring.

See Also

• Renovo
• Clinical trial
• Extracellular matrix
• Scar

Avotermin Resources
Most recent articles Ongoing trials	Wikipedia